Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 5/20 | 0.48 |
| ▸ | BRAF | P15056 | 5/20 | 0.48 |
| ▸ | CSF1R | P07333 | 2/20 | 0.48 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.48 |
| ▸ | DDR2 | Q16832 | 2/20 | 0.48 |
| ▸ | ARAF | P10398 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 14/20 | 0.37 |
| ▸ | TOP1 | P11387 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30598749 | 0.82 | RAF1 (0.65) | RAF1BRAFCSF1RDDR1DDR2 | |
| SCHEMBL24399631 | 0.76 | RAF1 (0.64) | RAF1BRAFCSF1RDDR1DDR2 | |
| SCHEMBL29638653 | 0.76 | RAF1 (0.64) | RAF1BRAFCSF1RDDR1DDR2 | |
| SCHEMBL30401790 | 0.71 | RAF1 (0.53) | RAF1BRAFCSF1RDDR1DDR2 | |
| SCHEMBL25378433 | 0.71 | RAF1 (0.53) | RAF1BRAFCSF1RDDR1DDR2 | |
| SCHEMBL24399732 | 0.71 | RAF1 (0.54) | RAF1BRAFCSF1RDDR1DDR2 | |
| SCHEMBL24399610 | 0.70 | BRAF (0.71) | RAF1BRAFCSF1RDDR1DDR2 | |
| SCHEMBL30402839 | 0.70 | BRAF (0.71) | RAF1BRAFCSF1RDDR1DDR2 | |
| SCHEMBL24399761 | 0.70 | BRAF (0.56) | RAF1BRAFCSF1RDDR1DDR2 | |
| SCHEMBL29638586 | 0.70 | BRAF (0.56) | RAF1BRAFCSF1RDDR1DDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116903626-A | Aryl amide compound, pharmaceutical composition containing same, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2023-10-20 | — | — | CN | disclosed |